

Daily evidence digest

8 November 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 in Victoria, COVID-19 sequelae in cancer patient survivors, breakthrough infections

Peer reviewed journals featured:

- Observational studies on:
 - The epidemiological features of COVID-19 epidemics in Victoria [here](#)
 - Prevalence and impact of COVID-19 sequelae in cancer patient survivors [here](#)
 - The early impact of the US COVID-19 vaccination program [here](#) and associated commentary [here](#)
 - SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination [here](#)
 - Potential global impacts of alternative dosing regimen and rollout options for Vaxzevria (AstraZeneca) vaccine [here](#)
 - Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine [here](#)
 - Estimating the impact of virus testing strategies on the COVID-19 case fatality rate [here](#)
 - The association between mRNA vaccination, COVID-19 hospitalisation, and disease severity [here](#) and a linked editorial on breakthrough infections [here](#)
- An editorial on investing in good data for a strong pandemic response [here](#)

Letters and correspondence discussed:

- Disparities in use of video telemedicine in US patients with limited English proficiency during COVID-19 [here](#)

Pre-peer review articles featured:

- The REACT-1 interim report on high and rising prevalence of SARS-CoV-2 infection in England [here](#)
- Waning of the humoral response to SARS-CoV-2 in pregnancy [here](#)
- Downsizing of contact tracing during COVID-19 vaccine roll-out [here](#)
- Use cases for COVID-19 screening and surveillance with rapid antigen-detecting tests [here](#)
- A third dose of Sinovac (CoronaVac) or Comirnaty (Pfizer) vaccine in adults with two doses of Sinovac (CoronaVac) [here](#)

Guidance and reports

- The World Health Organization published guidance on planning for mass gatherings during COVID-19 [here](#)

News and blogs

- The UK becomes first country to authorise antiviral molnupiravir [here](#)
- US doctors begin administering vaccine to children aged 5-11 years [here](#)
- When masks most useful [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).